Safety and immunogenicity study of GlaxoSmithKline’s Herpes Zoster subunit vaccine (HZ/su) when given on a two-dose schedule to adults at least 50 years of age (YOA) with a prior episode of Herpes Zoster

Trial Identifier: 204939
Sponsor: GlaxoSmithKline
Start Date: September 2019
Primary Completion Date: February 2024
Study Completion Date: February 2024
Condition: Other - Conditions

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
Russian Federation Barnaul, Russian Federation, 656043
Russian Federation Gatchina, Russian Federation, 188300
Russian Federation Moscow, Russian Federation, 115478